Novartis's Kymriah wins EU approval for blood cancer treatment
Swiss drugmaker Novartis on Monday received European Commission approval for Kymriah, its CAR-T cell therapy, to treat children with a form of leukemia and adults with lymphoma.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Children | Health | Leukemia | Lymphoma | Switzerland Health